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Abstract 
Post-translational modification confers diverse functional properties to immune system proteins. 
The composition of serum proteins such as immunoglobulin G (IgG) strongly associates with 
disease including forms lacking a fucose modification of the crystallizable fragment (Fc) 
asparagine(N)-linked glycan that show increased effector function, however, virtually nothing is 
known about the composition of cell surface receptors or their bound ligands in situ due to low 
abundance in the circulating blood. We isolated primary NK cells from apheresis filters following 
plasma or platelet donation to characterize the compositional variability of Fc g receptor IIIa / 
CD16a and its bound ligand, IgG1. CD16a N162-glycans showed the largest differences 
between donors; one donor displayed only oligomannose-type N-glycans at N162 that correlate 
with high affinity IgG1 Fc binding while the other donors displayed a high degree of 
compositional variability at this site. Hybrid-type N-glycans with intermediate processing 
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 3 
dominated at N45 and highly modified, complex-type N-glycans decorated N38 and N74 from all 
donors. Analysis of the IgG1 ligand bound to NK cell CD16a revealed a sharp decrease in 
antibody fucosylation (43.2 ±11.0%) versus serum from the same donors (89.7 ±3.9%). Thus, 
NK cells express CD16a with unique modification patterns and preferentially bind IgG1 without 
the Fc fucose modification at the cell surface. 
 
Introduction 
Molecules at the cell surface mediate intercellular interactions and reveal characteristics 
fundamental to the lineage and function of that cell. These antigens are often also critical to cell 
function. For example, Fc g receptor IIIa (FcgRIIIa / CD16a) is a protein expressed on natural 
killer (NK) cells that binds immunoglobulin G (IgG), triggering a protective immune response 
(Figure 1A). The levels of CD16a and CD56 reflect the developmental stage with mature NK 
cells exhibiting a CD56DIM/CD16+ phenotype (1). Similar approaches to define and isolate cell 
types overlook one known source of variability that contributes to function: post-translational 
modification. Every individual protein at the cell surface is potentially unique due to the 
compositional variability of post-translational modifications (PTMs) at multiple sites that are not 
directly encoded in the genome (2). Furthermore, composition of the PTMs impacts protein 
function and possibly immune cell response including CD16a and CD56 on NK cells, CD64 
(FcgRI) as well the T cell receptor on T cells among others not covered here (3-7). Aberrant 
PTMs associate with many diseases but the native composition of only a few endogenous 
proteins is defined (including, but not limited to ref. (8-11)). Thus, a complete description must 
include a definition of PTMs to understand the potential plasticity of any cell response. 
 PTM composition cannot be predicted from a DNA sequence. The predominant 
mammalian PTM, asparagine-linked (N-)glycosylation, is heavily altered following the initial 
protein modifying reaction by any number of hundreds of glycosyltransferases and 
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 4 
glycosylhydrolases in the ER and Golgi, generating a large distribution that may include any of 
the more than 3,400 known human N-glycoforms at any single site (Figure 1B) (12). This 
heterogeneity presents an obstacle to defining protein composition along with the tiny amount of 
any individual receptor in the human body. Furthermore, many integral membrane proteins 
require detergents during purification, reducing the sensitivity of mass spectrometry (MS)-based 
approaches (13). Unfortunately, recombinant expression appears to provide no salvation as the 
expressing cell dramatically impacts processing (6). 
 Little is known about CD16a processing, though composition impacted the affinity for 
IgG1 Fc in vitro (6, 7, 14). Presenting minimally-remodeled N-glycans at N162 increased affinity 
by up to 50 fold (14, 15). N45 glycosylation also contributes to affinity by stabilizing CD16a 
structure and roles for the three remaining N-glycans remain undefined (15). Though it is not 
clear how CD16a PTMs impact immune function, a wealth of evidence indicates that the 2-4 fold 
affinity increase due to a common polymorphism (V158) improved clinical outcome following 
treatment with therapeutic monoclonal antibodies (mAbs) when compared to patients 
expressing F158 (16-21). Thus, there is a possibility that CD16a PTM composition impacts 
antibody binding affinity in vivo.  
 IgG1 from serum is likely the predominant ligand for CD16a under normal conditions. 
IgG3 exhibits higher affinity but is unlikely the major ligand because the concentration in serum 
is much less than IgG1 (17, 22-24). IgG, like CD16a, is modified. N-glycosylation of the IgG 
crystallizable fragment (Fc) is required for receptor binding and changes in Fc N-glycan 
composition are associated with disease (including, but not limited to ref. (8, 25-29)). Of the 
potential modifications to the Fc N-glycan, fucosylation of the core N-acetylglucosamine 
(GlcNAc) residue occurs at high levels in human serum (~85-95%) though antibodies lacking 
this modification bind CD16a with higher affinity and elicit antibody-dependent cell-mediated 
cytotoxicity at lower antibody concentrations (30, 31). IgG1 is abundant in serum (~10 mg/mL) 
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 5 
and though changes in serum IgG and antigen-specific IgG composition are known (29, 32, 33), 
the distribution of IgG glycoforms that are bound to effector cells remain undefined.  
 We adopted a targeted approach to define the composition of CD16a and its bound IgG 
ligand from NK cells. NK cell CD16a is the primary receptor for mAb therapies though CD16a is 
also expressed by “non-classical” monocytes and macrophages (34). A preliminary study 
showed the unexpected presence of minimally-remodeled N-glycans from NK cell CD16a, 
though it was unclear if these forms occupied N162 (6). We obtained mononuclear leukocytes 
from individual donors and isolated NK cells that express high levels of CD16a. NK cells 
constitute only a minor fraction of the total peripheral blood cell count (1-6% of leukocytes (35)). 
We then purified CD16a and IgG1 to analyze the composition of PTMs at each modified site to 
demonstrate that apheresis is a viable source of cell type specific cell surface receptors and 
their bound ligands. 
 
Experimental procedures 
Experimental design – The healthy human donors were de-identified and not directly enrolled 
for the study but rather randomly selected based on scheduled donations at the blood centers. 
Additionally, one donation provides enough material for only one analysis thus, it was not 
possible to replicate the analysis with material from the same donor. The consistent rate of 
migration of CD16a in SDS-PAGE gel from over 20 donors in our laboratory and in other studies 
suggested relatively homogenous distribution of PTMs on different donors thus, biological 
replicates are represented by five donors.  
Cell isolation – Apheresis filters were obtained from the DeGowin Blood Center (Iowa City, IA) 
and LifeServe Blood Center (Ames, IA). Donors were provided a health screen including 
measurements of body temperature, blood pressure, pulse and blood count. A review 
exemption from the Institutional Review Board at Iowa State University was obtained prior to 
sample collection. An aliquot of cells (50 μl) was centrifuged at 3000 x g for 10 min, serum and 
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 6 
cells were collected and stored separately at -80 °C. NK cells were isolated and validated as 
described (6). 
NK cell activation – NK cells were washed with PBS, then incubated at a density of 5×106 
cells/ml in RPMI 1640 medium (Thermo) with 0.1% FBS (pretreated to remove IgG) and 1 μg/ml 
phorbol 12-myristate 13-acetate (PMA; Sigma) for 60 min at 37°C. Medium containing CD16a 
was centrifuged at 1000 × g for 10 min and stored at -80 °C. 
CD16a immunoprecipitation – NK cells were lysed with 100 mM Tris, 100 mM sodium chloride, 
5 mM EDTA, 5 mm oxidized glutathione, 10 μM potassium ferricyanide, 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 10 mg/mL dodecyl maltoside (DDM), pH 8.0, 4 °C; 250 μl 
per 1×107 cells. The lysate was clarified by centrifugation at 10,000 × g for 10 min at 4 °C and 
the supernatant frozen at -80° C. Protein G Sepharose resin (GE healthcare) was added to 
thawed lysate (5 μl per 200 μl lysate) for 60 min at 4 °C with mixing and then removed by 
centrifugation at 500 × g for 5 min. The supernatant was sonicated in bath sonicator for 1 min. 
Anti-hCD16 (3G8)-coupled resin was prepared as described (6) but as an aglycosylated variant 
(N297Q) and coupled at 2.3-2.6 mg/ml, then incubated with lysate (10 μl per 200 μl lysate) 
overnight at 4° C with mixing. Resin was washed 2x600 µL of lysis buffer by centrifugation (500 
× g for 5 min) to pellet the resin. This was followed by 2x1 volume washes with 50 mM Tris, 100 
mM sodium chloride, pH 8.0 and 2x1 volume with 50 mM ammonium carbonate, pH 8.0. CD16a 
was eluted with 200 μl of 54.9% acetonitrile (ACN), 45% water and 0.1% trifluoroacetic acid 
(TFA). Each elution fraction was neutralized by with 26 μl 1M ammonium carbonate. CD16a 
was purified from the medium following PMA treatment in a similar manner. Except the medium 
was sequentially passed through columns containing 50-100 μl protein G Sepharose followed 
by 100 μl 3G8 agarose resin. CD16a yields were assessed by western blot as described (6).  
IgG immunoprecipitation from serum and NK cell lysate – Serum IgG was isolated by diluting 2 
µL serum into 500 µL 100 mM Tris, 100 mM sodium chloride, 10 mg/mL dodecyl maltoside, pH 
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 7 
8.0 and incubating with 50 µL Protein G Sepharose resin for 60 min at 4 °C with mixing. NK cell 
IgG was obtained from Protein G Sepharose resin incubated with the NK cell lysate as 
described above. Resin was washed as described above but IgG was eluted with 5 x 300 µL 
100mM Formic Acid, pH 2.5 and immediately neutralized with 150 µL 1M ammonium carbonate, 
pH 8.0 (27). IgG yields were determined with western blots using 5% of the eluted fraction and a 
rabbit anti-hIgG antibody (Thermo, 0.24 µg/ml) with goat anti-rabbit IgG HRP antibody 
(Research and Diagnostic Systems, 1:1000 dilution).  
CD16a and IgG proteolysis – The CD16a ACN:water:TFA elutions were combined, lyophilized 
and resuspended in 120 μl 50 mM ammonium carbonate, 10% (v/v) methanol, pH 8.0. The 
samples were boiled at 95 °C for 5 min and cooled on ice. Sequencing grade chymotrypsin 
(Millipore Sigma) and GluC (Promega) were reconstituted according to the manufacturer’s 
guidelines and added to the CD16a sample at an enzyme:CD16a molar ratio of 1:30 and 1:20, 
respectively, and incubated at 25 °C for 18 h. Then, 75 ng of each enzyme was added followed 
by incubation at 37 °C for 4 h. Chymotrypsin cleaves C-terminal to phenylalanine, tyrosine, and 
tryptophan and less efficiently at leucine. Glu-C cleaves C-terminal to glutamic acid. 
Elution fractions from IgG isolation were similarly combined, lyophilized, resuspended in 
120 μl 50 mM ammonium carbonate, pH 8.0 and boiled. Sequencing grade Trypsin (Promega) 
was reconstituted and added at an enzyme:IgG molar ratio of 1:20 before incubation at 37 °C 
for 18 h. Trypsin cleaves C-terminal to the lysine and arginine residues. Next, dithiothreitol was 
added (5 mM final) to CD16a and IgG samples and incubated at 37 °C for 1 h, followed by 
iodoacetamide (15 mM final) and incubation at 25 °C for 1 h in the dark. The samples were 
centrifuged at 10,000 × g for 3 min and the supernatant was lyophilized. 
Glycopeptide enrichment and detergent removal – Samples were resuspended in 10 μl water 
and purified using a glycopeptide enrichment kit (Millipore Sigma) except that the elution was 
repeated three more times than suggested. The eluted glycopeptide fractions were combined 
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 8 
and lyophilized. The supernatant from CD16a samples containing mostly unmodified peptides 
was washed with saturated ethyl acetate in water and lyophilized (36).  
Mass spectrometry – Samples were resuspended in 5 μl of 5% ACN, 0.1% TFA acid in water 
then separated on a 75 μm × 20 cm fused silica capillary (Agilent Technologies) column/emitter 
attached to an EASY nLC-1200 LC system with a Nanospray FlexIon source (Thermo). The tip 
of this column was fabricated using a laser puller (Sutter P-200) and was packed with 5 µm 
Agilent Zorbax C18 medium using a pressure cell (Next Advance). The remainder of the column 
was packed with either the same material or with 3 µm UChrom C18 medium (nanoLCMS 
Solutions). Samples were eluted with a 0% to 35% gradient of Buffer B (80% ACN and 0.1% 
formic acid in water) in Buffer A (0.1% formic acid in water) at 300 nl/min over 60 min. Buffer B 
was then increased to 70% over 10 min, increased to 100% for 10 min and held for 3 min. 20 μl 
of 100% Buffer A (0.1% formic acid in water) was then passed through the column at 400 bar to 
equilibrate the column. Each sample run was followed by a blank run with 5 μl of Buffer A 
injected instead of sample. The LC eluent was analyzed on a Q Exactive Hybrid Quadrupole-
Orbitrap Mass Spectrometer with an HCD fragmentation cell (Thermo). MS spectra were 
collected in positive ion mode with a scan range of 600-2500 m/z (for glycopeptides) or 266-
2500 m/z (for peptides). Data-dependent acquisition was obtained using an 80 ms MS1 window 
and up to 20 of the most abundant ions were selected for HCD fragmentation at a stepped 
normalized collision energy (NCE) of 17, 27 and 37 eV (for glycopeptides) or 27 eV only (for 
peptides). Ions visible at 600 m/z in the MS2 spectra are carryover from a calibration standard. 
Data analysis – The CD16a glycopeptides were initially identified using Byonic (Protein Metrics, 
v. 2.12.0; search details given below) that identified two of the five N-glycopeptides (N45 and 
N162). The remaining glycopeptides were identified through manual evaluation of the spectra by 
matching expected and observed parent ion mass, presence of characteristic oxonium ion 
species and the presence of a fragment corresponding to peptide with one HexNAc in MS2 
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 9 
spectra. Once retention times for each glycopeptide were identified, we generated a 
comprehensive mass list for all possible CD16a glycopeptides based on species identified by 
manual assignment in one NK cell dataset (NK13) and N-glycans identified in a previous NK cell 
CD16a glycomics study as well as any potential N-glycan variations (6). These mass lists were 
used to probe raw MS1 data to identify other species not originally found in the manual and 
Byonic searches. MS2 spectra were available for most species and annotated using 
Glycoworkbench (see the supplemental MS2 annotations) (37). For the minority of species that 
did not give rise to high quality MS2 spectra, identifications were made based on masses 
observed in the MS1 spectra (with errors < 0.05 Da), comparable retention times to species with 
the same peptide backbone, and predictable differences to identified peaks in the same dataset 
(e.g. with a mass difference of 365.13 Da). The IgG1 glycopeptide mass list was generated from 
previously identified serum IgG1 glycoforms and annotated MS2 spectra for each species are 
likewise available as supplemental MS2 spectra (27). Tier 3 quantification of glycopeptides was 
performed for all datasets using these mass lists. MS1 isotope mass and intensities over a 
retention time range unique for each ion were extracted from the RAW spectrum file into a .cvs 
file using Xcalibur Software (Thermo Fisher Scientific). Glycopeptide intensities were measured 
using an R script (see the Supplement) to report intensities of first seven isotopologue peaks 
from the extracted raw MS1 data. Each species was validated for mass accuracy, isotopologue 
intensity distribution and MS2 spectra (where available). Intensities from different charge states 
were summed and the relative abundance was calculated using the summed intensity of all 
observed glycoforms on same peptide as a reference.  
Peptides were identified from the glycopeptide enrichment flow-through fraction using 
Protein Metrics Byonic software (Version 2.12.0). The search parameters included Cleavage 
site (FYWEL), Cleavage side (C-terminal), Digestion specificity (Semi specific (slow)), Missed 
cleavages (2), Precursor mass tolerance (5 ppm), Fragment mass tolerance ( 0.05 Dalton), 
Recalibration (lock mass) (none), maximum precursor mass (5,000), Precursor and mass 
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charge assignments (Compute from MS1), Maximum # of precursors per scan (10), smoothing 
width (0.01 m/z) and the following modifications included (in addition to N- and O-glycan 
databases): Carbamidomethyl / +57.021464 @ C | fixed; Deamidated / +0.984016 @ N | 
common1; Acetyl / +42.010565 @ Protein N-term | rare1; Phospho / +79.966331 @ C, D, H, K, 
R, S, T,Y | common2; HexNAc / +203.079373 @ N,S,T | common1. Each identified glycopeptide 
was manually validated. Monosaccharides were determined by mass, and isomers were not 
distinguished. 
 IgG N-glycan composition was quantified using the completely digested peptide 
(EEQYNSTYR), however, N-glycans on NK cell IgG from NK12 and NK13 were quantified using 
a partially digested peptide (TKPREEQYNSTYR) due to its higher abundance in these two 
datasets. 
Donor genotyping – Total RNA was isolated from frozen pellets using the TRIzol reagent 
(Thermo). cDNA was synthesized from 1 μg total RNA using the High-Capacity RNA-to-cDNA 
kit (Thermo) according to the manufacturer protocol. Full-length fcgr3a cDNA was amplified 
using forward (5’-CAGTGTGGCATCATGTGGCAG-3’) and reverse (5’-
TTTGTCTTGAGGGTCCTTTCT-3’) primers and sequenced at the ISU DNA Facility. Genomic 
DNA was isolated from the interphase layer formed during RNA isolation with the TRIzol 
reagent. Genomic segments covering CD16a exon 4 (partial), intron 4-5 and exon 5 (partial) 
were amplified using forward (5’-CACAGCTGGAAGAACACTGC-3’) and  reverse (5’-
GAAAGTCCAGGCACACCACTC-3’) primers for the upstream section and forward (5’-
TGAAGTAACCGAGGTGCAAA-3’) and reverse (5’-TTTGTCTTGAGGGTCCTTTCT-3’) primers 
for the downstream section that partially overlaps with the first fragment. The segments were 
cloned into pGEM-T Easy Vector (Promega) and sequenced.   
 
Results 
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NK cell CD16a from apheresis – We recovered 2.5-25x107 NK cells from each of five healthy 
donors following apheresis (Table 1; Figure S1) (38). CD16a from three donors was purified 
following detergent lysis with a yield of 1.7 μg, 0.7 μg and 2.0 μg from the NK08, NK09 and 
NK11 donors, respectively. The eluted protein migrated between 53 and 59 kDa in SDS-PAGE 
(Figure S2). We also purified CD16a without detergent following PMA activation to release 
nearly the entire extracellular portion of the mature receptor that we expect is predominantly 
borne on the cell surface, yielding 0.3 μg and 0.5 μg of CD16a from the NK12 and NK13 
donors, respectively (Figure 1A and S2; (39-41)).  
LC-MS/MS analysis of CD16a – We identified peptides corresponding to nearly the entire CD16 
sequence with the exception of the hydrophobic transmembrane region which was not identified 
(Figure S3). The analysis of identifying peaks in MS2 spectra let to the definitive identification of 
peptides and PTM composition, and in some cases these spectra also provided clues to PTM 
configuration (Figure 2 and S4). N-glycans were the only type of CD16a PTM observed. We 
identified 211 unique CD16a glycopeptides from five donors (Table 2 and S1). Though 
detergent extraction led to greater protein yields, PMA-released CD16a provided a greater 
number of ions. This is likely due to an inability to completely remove detergent following lysis; 
no detergent was used for purifying PMA-released CD16a. In addition to the identification of N-
glycan modifications, two peptides showed partial deamidation of the asparagine residue, 
though it is not clear if these modifications occurred in situ or during the purification 
(LQNGKGRKY and FHHNSDFY; Figure S3). 
CD16a site impacts processing – N-glycopeptides from the same site of different donors 
showed greater similarity than different N-glycopeptides from the same donor (Figure 1D). N-
glycans at N38, N74 and N169 showed minimal variability between donors and were almost 
exclusively complex types. N-glycans at N45 and N162 showed greater variability between 
donors with N45 displaying predominantly hybrid types with some complex-type glycans and 
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N162 with mainly complex-type glycans showed the greatest variability between different 
donors. 
 The profiles of detergent-solubilized CD16a and CD16a released by PMA activation 
showed important differences. CD16a released from PMA-activated NK cells contained no 
oligomannose forms in contrast to detergent solubilized CD16a with 2-6% of N45 glycopeptides 
containing oligomannose forms. N45 is ideal for such comparisons due to superior ion yields 
from each donor (Table 2). This result suggests that a small amount of folded but immature 
CD16a is retained in NK cells following PMA-induced activation.  
Donor-to-donor variability of the N162-glycan composition – This proteolysis strategy links 
V/F158 and N162 on a peptide containing a single glycan (Table 2). Donor allotype was 
confirmed for four of the five donors by sequencing CD16a cDNA; however, we observed 
peptides corresponding to both alleles from the NK09 donor but only found cDNA corresponding 
to F158 (Figure S5) that may be explained by the greater abundance of the F158-containing 
transcripts in the NK09 NK cells biasing the cDNA sequencing results. If both alleles are present 
with equal copy numbers, no such variability is expected in the genomic DNA. Sequencing the 
genomic DNA from the NK09 donor confirmed the presence of both alleles along with multiple 
mutations in both coding and non-coding regions of the V158 allele when compared to the 
consensus CD16a sequence (Figure S5).  
CD16a glycopeptides with the F158 residue yielded less intensity and as a result a lower 
number of identified glycoforms (14 forms) when compared to V158 peptides in heterozygous 
donors (33 forms) suggesting either a reduced abundance of the F158 peptide or lower 
ionization efficiency of this glycopeptide (Table 1 and S1).  
 The predominant N162 glycopeptide contained a monosialylated, core fucosylated, 
biantennary complex-type N-glycan (Figure 3 and Table S1), though a comparison of donors 
showed substantial variability in the abundance of under-processed forms. Donors contained a 
range from 5% to 42% of hybrid-type N162-glycans, with the exception of NK09 N162(V158) 
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that showed only oligomannose-type N-glycans, as confirmed by MS2 spectra (Figure S4). One 
could argue that the NK09 donor expressed only under-processed CD16a V158 that was 
trapped in intracellular vesicles. If this were true, the other four sites should include roughly 50% 
of under-processed forms when in most cases none appeared (Figure 1D). Thus, NK09 
expressed CD16a with minimal processing at the N162(V158) and N169 (discussed below) 
sites but with processing comparable to the other four donors at the three other N-glycosylation 
sites. Oligomannose-type N162-glycans also appeared in spectra from the NK08 donor but at a 
lower level compared to NK09. 
The appearance of minimally-processed CD16a N-glycans in this analysis is consistent 
with our recent glycomics study that revealed a significant number of oligomannose forms in the 
pool of CD16a N-glycans from three older donors (67-79y (6)). The age comparison is notable 
because NK09 is one of the oldest in this pool of five donors at 59, however, the prevalence of 
oligomannose only at V158 protein might also be due to age independent factors such as 
unique point mutations in the sequence encoding the NK09 CD16a V158 protein (Table 1 and 
Figure S5). The presence of oligomannose N-glycans at N162, as noted above, increases 
affinity for IgG1 Fc (6, 14). Thus, NK08 and NK09 may be expressing CD16a glycoforms that 
bind with greater affinity than NK11, NK12 and NK13 with higher proportions of complex-type 
N162-glycans. It is unclear how the hybrid type N162-glycans impact antibody binding affinity. 
 A paucimannose N162-glycan appeared in detergent solubilized samples with F158 
glycopeptides showing higher levels than V158 (GlcNAc2Mannose3Fucose1; Figure 3 and S4). 
We observed this glycoform in our recent glycomics analysis (6), though it is not generally 
expected on mature N-glycoproteins and likely results from partial degradation in the cell  (2). 
Partially degraded paucimannose glycans also recently appeared with proteins localized to the 
neutrophil granule (42).  
CD16a N45 displays predominantly hybrid-type N-glycans – The N45-glycan is unique among 
the five CD16a modifications because it forms measurable intramolecular interactions between 
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glycan and polypeptide residues that restrict mobility and likely limit glycan processing (15). As 
expected, N45 glycoforms showed the highest proportion of minimally-processed forms from all 
five donors among 47 unique glycoforms identified (Table 2, Figures 1D and 4).  
Though the N45 glycan shows restricted processing, the termini received a high degree 
of sialylation. Monosialylated hybrid types accounted for the majority of the N45-glycans and 47-
68% of the total forms at this site (Figure 4; Table S1). Complex-type bi- and tri-antennary 
glycans comprised the second most abundant group (15-26%) (Figure S4). The relative 
abundance of hybrid and complex glycoforms were highly comparable for four of the five 
donors; NK13 had higher abundance of complex-type N-glycans (43%) compared to an average 
of 21% for the other donors. NK13, unlike the other donors, also contained N45-glycans with 
highly processed N-acetyllactosamine (LacNAc) repeats (10% of the complex-type N-glycans at 
this site from this donor). Oligomannose forms were only observed in the detergent solubilized 
samples and produced the lowest ion intensities of any form, representing less than 6% of the 
N45-glycoforms. 
We identified two features of the N45 glycopeptides that complicated data analysis. First, 
N45-glycan composition impacted proteolysis in the presence of residual detergent that 
remained following specific washes to remove lipids and detergents. Less fucose appeared in 
the smaller N45 glycopeptide #1 than the longer N45 glycopeptide #2 (Table 2; Figure S4). 
CD16a purified following PMA activation did not reveal a similar bias.  
Second, we observed some N45 glycopeptide ions in samples from all donors with an 
additional mass of 79.96 Da (Figure S4). Similar modifications were not observed at other sites 
or with recombinant CD16a. The species eluted later than unmodified N45 glycopeptides in 
detergent-solubilized CD16a. Analysis of MS2 spectra from relevant species did not reveal the 
modification location, or whether it is covalently attached to the carbohydrate or amino acid 
residues. N-glycans are known to contain phosphate or sulfate modifications that correspond to 
a mass change of 79.9663 or 79.9658 Da, respectively (10). 
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The predominant N38 and N74 glycans contain multiple N-acetyllactosamine repeats – As the 
most highly processed sites identified for NK cell CD16a, N38 and N74 displayed only highly 
modified, complex-type N-glycans (Figure 5). One characteristic features is the presence of 
LacNAc repeats at both sites that is evident from the glycan mass as well as a characteristic 
oxonium ion in MS2 spectra consisting of a single N-acetylneuraminic acid, two hexoses and 
two N-acetylhexosamines (mass = 1022.36 Da; Figure S4 and Table S1). Furthermore, we 
believe the N38 and N74 glycans are predominantly tetraantennary due to presence of four, and 
no more than four, sialic acids on 86% and 99% of the forms found at N38 and N74, 
respectively, as well as the complete absence of characteristic polysialic acid fragments in the 
MS2 spectra.  
The N169 glycan is a complex type – CD16a purified following PMA activation provided greater 
intensity and depth of coverage than CD16a solubilized with detergent due to ADAM17-
catalyzed cleavage that reduced the size of the PMA-activation peptide (40, 41). In both 
situations, however, a monosialylated, biantennary, core fucosylated complex-type glycan 
proved to be the predominant form, representing as much as 43% to 47% of the N169 total in 
PMA released samples. This position was preserved among all samples, except that from NK09 
(Figure 6). Apart from an atypical truncated form of the N169 peptide that is not consistent with 
ADAM17 cleavage or chymotrypsin/Glu-C cleavage, donor NK09 displayed predominantly 
hybrid type N169-glycans (63%) with fewer complex types (37%) (Table 2; Figure S4). This 
restricted processing of the NK09 N169 site is similar to the nearby N162 of the NK09 donor 
which showed predominantly under-processed forms (Figure 6D). It is unclear if the mutations 
present in the NK09 CD16a V158 genomic sequence impact N162 and N169 N-glycan 
processing (Figure S5). 
NK cells retain IgG1 lacking core fucose – Freshly isolated NK cells exhibited IgG staining in a 
FACS experiment that correlate with amount of CD16a staining, indicating NK cells bound IgG 
primarily through CD16a (Figure 7A). Data from the right hand panel of Figure 7A fit to a line 
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with an R-squared value of 0.70 and a repeat experiment showed similar results with an R-
squared of 0.75 (data not shown). A high average percentage of IgG purified from the NK cell 
lysates of nine donors (45% of the potential IgG, based on the mass of CD16a in the lysate; 
Table 1). We also purified IgG from the serum of each donor for comparison (NK06 excepted; 
Table 1). IgG1 purified from NK cells showed a striking lack of fucose (56.8 ±11.0%) compared 
to serum (10.3 ±3.9%) (Figure 7). The rank order of the top fucosylated and afucosylated forms 
remained unchanged between the NK cell and serum fractions, revealing fucosylation level as 
the primary difference. Furthermore, oligomannose Fc N-glycans lacking core fucosylation 
appeared on NK cells. We did not detect these minimally-processed N-glycans in serum 
samples.  
Discussion  
Powerful connections between the post-translational modification of serum proteins and immune 
system function are emerging as new technologies provide resolution at the level of a single 
donor and at a single modified site (27, 43, 44). These prior studies likely represent a tiny 
sample of the larger group of molecules that display clinically relevant and variable 
modifications. Little is known about PTMs on endogenous human membrane proteins not 
because it is unimportant, but because of low abundance in a single donor. Here we 
characterized the antibody-binding receptor CD16a from primary human NK cells recovered 
from apheresis filters and discovered unexpected variability between donors. We believe this 
strategy is applicable to characterize PTMs of immune cell receptors and will lead to studies that 
will define how PTMs vary and impact immune system function. 
 
Enrichment of IgG lacking fucose – The functional receptor-binding unit of IgG1 is the Fc, a 
dimer that binds asymmetrically to CD16a (45). This asymmetric mode will bind to one of the 
two Fc chains providing the greatest affinity. For example, Fc containing both a fucosylated N-
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glycan and a glycan lacking fucose will preferentially bind CD16a in a manner that places the Fc 
half lacking a fucose adjacent to the CD16a N162-glycan (46). Furthermore, IgG1 N-glycans on 
the same molecule are not necessarily identical (47) but it is possible that a subset of the serum 
IgG is symmetrically afucosylated thus dominating the antibodies on the NK cells; high levels of 
afucosylation were observed for antigen-specific responses (29, 44, 48). We expect 
symmetrically afucosylated IgG to be a minority of the total serum IgG and apply a distributive 
model for analysis. Thus, at 10% serum fucosylation, we expect that 95% of the NK cell-bound 
IgGs contain one fucosylated N-glycan and one N-glycan lacking fucose with a maximum 
possible level of fucose of 47% given a distributive model. This calculated value is comparable 
to the measured value of 43.2 ±11.0%. Thus, the majority of CD16a on NK cells is likely bound 
to IgG1 with at least one N-glycan lacking a core fucose residue.  
 The enrichment of IgG1 lacking fucose on the surface of NK cells may provide the body 
a mechanism to prioritize a specific response. It is known that antigen-specific antibodies can 
exhibit dramatically different glycan composition when compared to bulk serum IgG in the same 
body, including large differences in fucosylation (29, 32, 33). These substantial differences in 
antibody composition predict that an antigen specific antibody response lacking fucose would 
result in NK cells binding more of that antibody than other serum antibodies with higher levels of 
fucosylation, potentially priming NK cells. This prioritized response is expected to be specific to 
NK cells because CD16a is the only FcgR expressed on NK cells from most donors in contrast 
to monocytes, neutrophils or resident macrophages that express a mixture of FcgRs including 
CD32a and CD64 that don’t exhibit a preference for IgG antibodies that lack fucose (49, 50). 
Donor-specific variability in CD16a processing – Even though N-glycosylation is affected by a 
range of different factors, the similarities between the N-glycosylation profiles of NK cell CD16a 
from five relatively diverse donors suggests the presence of conserved biological features that 
serve specific irreplaceable functions. CD16a with the most abundant N-glycans identified at 
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each site is shown in Figure 1C. These modifications are roughly scaled to the size of the 
protein to demonstrate that the modification adds ~13 kDa to the 20 kDa extracellular domain.  
Modifications at N162 showed the greatest variability in processing after comparing the 
results from different donors. As described above, the composition of the N162-glycan affects 
affinity of CD16a for IgG1 (6, 14, 51, 52). Though some compositional variability was expected, 
the degree of donor specific variability in the abundance of minimally processed forms identified 
here was not anticipated (Figure 3). This observation suggests that NK cells have the capability 
to tune IgG binding and potentially the threshold for activating ADCC by changing the N-glycan 
composition. Conditions in the body, including cytokine levels, are known to affect N-glycan 
composition (53-57). A demonstration of similar or greater variability in a much larger number of 
apheresis filters from healthy and inflamed individuals would support this hypothesis, and 
supports the importance of similar studies with site-specific resolution of CD16a from a single 
donor. 
Composition of the N45-glycan does not appear to impact affinity, but its presence is 
required for high affinity interactions (14, 15). The appearance of a high percentage of hybrid 
forms is unexpected. N45 is often the least processed CD16 N-glycan, and this restriction may 
be due to intramolecular interactions that reduce N45-glycan accessibility during processing 
(15). It was further unexpected that the NK09 donor showed even less processing at N162 than 
N45. This indicates that additional CD16a-specific factors might contribute to processing. 
Though N-glycosylation at N38 and N74 does not impact affinity in vitro, these N-glycans 
may serve critical, likewise tunable roles in CD16a-mediated cell activation (14). For example, 
the observed LacNAc repeats have the potential to regulating receptor clustering at the NK cell 
surface. LacNAc repeats can serve as ligands for galectins, which were shown to modulate T-
cell activation by preventing T-cell receptor clustering (4). LacNAc repeats are added following 
the MGAT5-catalyzed addition of a GlcNAc residue to the N-glycan, forming a new branch point. 
IL-10 dependent expression of MGAT5 in CD8+ T-cells is known to modulate the immune 
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response (53). Similarly, MGAT5 is expressed in NK cells and may contribute to the NK cell 
response (58). 
We noted substantial differences in a comparison of the primarily hybrid-type NK cell 
CD16a N45-glycans and the predominance of oligomannose forms at comparable sites of 
CD16b expressed by neutrophils (59, 60). Furthermore, CD16b lacked complex-type N45-
glycans which represented 25% of the NK cell CD16a forms (Figure 1D). Other differences 
include CD16b N162 that showed higher branch fucosylation. CD16b revealed fewer hybrid 
N162 forms and the appearance of the fucosylated paucimannose N-glycan seen in CD16a. 
Even the highly processed sites N38 and N74 consistently showed less sialylation in CD16b 
compared to CD16a. These PTM differences likely represent important features that contribute 
to functional differences between CD16a and CD16b, in addition to the presence of a 
glycosylphosphatidylinositol anchor on CD16b and the G129 residue that provides high antibody 
binding affinity to CD16a (52). Considering the high structural and sequence homology of 
CD16a and CD16b, it will be informative to determine how conditions in the secretory pathway 
contribute to the observed N-glycan processing differences. 
Two recent studies characterized N-glycans from the related receptor CD16b. These 
studies purified soluble CD16b from a large volume of pooled serum or only the CD16b N45 and 
N162 glycans from neutrophils of individual donors (59, 60). Neutrophils and CD16b are much 
more abundant (30-80% of leukocytes), requiring a much smaller amount of blood to isolate a 
sufficient mass of receptor (~20 mL). Our studies represent a substantial advance towards 
characterizing cell surface proteins from a less abundant cell type.   
Implications of the Approach – This present study identified several important considerations for 
future studies of endogenous receptors. First, core fucosylation reduces cleavage at proximal 
protease sites, introducing potential bias in the analysis if peptides resulting from missed 
cleavages are not identified. For CD16a, the presence of a core fucose residue at N45 inhibited 
GluC activity at the adjacent amino acid residue (E46). Similar composition-dependent inhibition 
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was identified in trypsinized IgA (61) and alpha-1-acid glycoprotein (62). Second, the parallel 
analysis of both the peptide and glycopeptide-enriched fractions prevents glycopeptide ion 
suppression and provides the opportunity to identify less hydrophilic modifications. Third, signal 
intensity is enhanced by reducing the levels of residual detergent. Our observation that avoiding 
detergent in all purification steps increased signal was unexpected considering that the methods 
included extensive washes to remove residual detergent. This situation was avoided through 
PMA induction of NK cells that shed CD16a into the medium. Finally, analyzing peptides 
provides broad protein coverage and can identify functionally-relevant polymorphisms as shown 
for CD16a allotype that impacts mAb therapies and may be a risk factor for autoimmunity (17, 
63-66). 
In summary, these results demonstrate the feasibility of characterizing, in a donor, cell-
type and site-specific manner, PTMs from receptors and ligands on the surface of low-
abundance leukocytes in the peripheral blood, including: NK cells, T and B lymphocytes, and 
monocytes.  
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Supplementary data 
This article contains supplemental Figures S1 to S5 plus custom R Scripts 
Supplementary PDF with Glycopeptide MS2 Annotations and peptide specific MS Excel sheets 
containing the observed mass/charge, intensity and monosaccharaide composition of all 
annotated glycopeptide MS2 spectra.   
Additional tables in the MS Excel Worksheet 
MS Excel Table S1. Related to Figure 1. Relative abundance ofCD16a glycopeptide. 
MS Excel Table S2. Related to Figure 1. Raw Intensity data for each CD16a glycopeptide. 
MS Excel Table S3. Related to Figure 7. Relative abundance of IgG1 glycopeptide. 
MS Excel Table S4. Related to Figure 7. Raw Intensity data for each IgG1 glycopeptide. 
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Table 1. NK cell and serum donor information 
n.a. - not applicable 
n.d. - not determined 
 
 
 
 
 
 
 
 
 
 
Donor Gender Age ABO 
group 
Rh 
factor 
Date of 
collection 
NK cell 
count 
(×106) 
NK cell 
Viability 
(%) 
CD16a 
genotype 
CD16a form 
NK00 M 40 A + 01/25/2017 56.9 87 n.d. n.a. 
NK01 M 64 AB + 3/15/2018 74 73 V/F n.a. 
NK02 F 33 B + 3/15/2018 43.2 70 V/F n.a. 
NK04 M 43 B + 3/15/2018 80 88 F/F n.a. 
NK06 M 23 A + 5/22/2018 84.5 68 V/V n.a. 
NK08 F 37 O + 5/31/2018 91.7 75 V/F Detergent solubilized 
NK09 M 59 O - 6/7/2018 64.8 88 V/F Detergent solubilized 
NK11 M 63 A + 6/7/2018 252 68 F/F Detergent solubilized 
NK12 F 28 A + 8/28/2018 25.4 58 V/F Released by PMA 
NK13 M 49 O + 8/28/2018 157 82 V/F Released by PMA 
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Table 2. CD16a N-glycopeptides identified in this study. V/V, V/F or F/F indicate donor allotype. 
Site # Peptide 
Detergent solubilized Released by PMA # of unique 
glycoforms NK08 
(V/F) 
NK09 
(V/F) 
NK11 
(F/F) 
NK12 
(V/F) 
NK13 
(V/F) 
N38 
1 KDSVTLKCQGAYSPEDNSTQW 13 10 n.d. 4 6 16 
2 KCQGAYSPEDNSTQW 9 4 4 4 17 18 
N45 
1       FHNE 16 8 27 n.d. 2 29 
2       FHNESLISSQASSY 20 25 6 15 37 40 
N74 
1    RCQTNLSTLSDPVQLE 10 4 4 8 17 17 
2    RCQTNLSTL 8 2 7 n.d. n.d. 10 
N162 
(V158) 
1                 VGSKNVSSE 2 n.d. n.a. 5 5 6 
2       CRGLVGSKNVSSE 16 4 n.a. 8 20 29 
3     FCRGLVGSKNVSSE 1 n.d. n.a. 2 5 6 
N162 
(F158) 
4                   GSKNVSSE 3 2 8 1 1 9 
5                 FGSKNVSSE n.d. n.d. n.d. 2 3 3 
6       CRGLFGSKNVSSE n.d. n.d. n.d. 2 2 3 
N169 
1        TVNITITQGL 1 n.d. 3 n.d. n.d. 3 
2        TVNITITQGLA n.a. n.a. n.a. 7 16 17 
3        TVNITITQG n.a. 5 n.a. n.a. n.a. 5 
n.a. - not applicable 
n.d. - not detected 
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Figures  
Figure 1. CD16a is the primary Fc g receptor expressed on NK cells and is heavily 
modified with N-glycans. A. CD16a was isolated by either NK cell stimulation with PMA to 
release CD16a or by lysing the cell with detergent (DDM). B. An abbreviated representation of 
the N-glycan remodeling pathway in mammals is shown that generates a diverse repertoire of 
modifications. C. A cartoon of CD16a topology shows the extracellular, transmembrane and 
cytoplasmic domains as well as the most abundant N-glycans at the five sites, scaled to the size 
of the protein. D. The relative abundance of the three N-glycan types identified at each CD16a 
site from each of five donors (donor identifier is listed below the bar and N-glycosylation site 
above). Peptides containing N162 glycosylation also reveal donor allotype (V158 v. F158) and 
are reported separately. n.a. - not applicable. See also Tables S1-S2 and Figures S1 and S2. 
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Figure 2. MS2 spectra for the most abundant N-glycan at N45, N162 and N169. A. N45 
glycopeptide (from NK13). B. N162 glycopeptide (from NK08). A cysteine residue modified by 
iodoacetamide is indicated with a red “IAM”. C. N169 glycopeptide (from NK13). Inserts indicate 
the parent ion and charge as well as the observed and expected mass. Identification was based 
on mass of the parent ion, mass of fragmented ions and characteristic oligosaccharide oxonium 
ions. See also Table 2 and Figure S4. 
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Figure 3. Donor-to-donor variability of the N162-glycan composition. Each wheel 
represents the relative abundance of individual N-glycans from five donors and from both 
CD16a allotypes (V158 v. F158). Glycans are grouped by oligomannose (green), hybrid (blue) 
or complex type (red). The abundance of N162 glycans from CD16a-V158 was determined 
using N162 glycopeptide 2. Glycan abundance for CD16a-F158 were summed from the 
intensities of N162 glycopeptide 4 (NK08, NK09 and NK11) and N162 glycopeptide 5 (NK12 
and NK13). The N-glycan cartoons represent one possible configuration based on composition. 
n.a.- not applicable. See also Table 2 and Figure S4. 
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Figure 4. CD16a N45 displays predominantly hybrid-type N-glycans. Bars show the relative 
abundance of N45-glycan species accounting for 95.3% of the total observed glycopeptide 
intensity from five donors. The abundance of each species was determined by first measuring 
the relative abundance of each glycan within each dataset, then averaging the relative 
abundance from the five datasets. Glycopeptide 1 (NK08, NK09, NK11 and NK13) and 
glycopeptide 2 (all data sets) were used for these comparisons. The N-glycan cartoons 
represent one possible configuration based on composition. Glycan types are specified by color 
as in Figure 3. See also Table 2 and Figure S4. 
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Figure 5. The predominant N38 and N74 glycans contain multiple N-acetyllactosamine 
motifs.  A. An ESI-MS spectrum shows the distribution of N74 glycopeptides that eluted from 
49.20-61.10 min (IAM-modified glycopeptide 1; NK13 dataset). B. The predominant N38 
glycans account for 95.8% of the total observed N38 glycopeptide intensity (IAM-modified N38 
glycopeptide 2). C. The predominant N74 glycans account for 96.1% of the total observed N74 
glycopeptide intensity (IAM-modified N74 glycopeptide 1). The N-glycan cartoons represent one 
possible configuration based on composition. See also Table 2 and Figure S4. 
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Figure 6. The N169 glycan is a complex type. A. Ribbon diagram of CD16a highlighting 
N169. B. The two different CD16a isolation techniques generate two different glycopeptides that 
show similar processing. The predominant N169 glycans from CD16a released with PMA 
ionizes well. These forms account for 96.2% of the total observed N169 intensity from the NK12 
and NK13 donors (N169 glycopeptide 2). C. N169 glycopeptides isolated from CD16a purified 
using detergent lysis of NK cells provided fewer observations from the NK08 and NK11 donors 
(N169 glycopeptide 1). D. CD16a glycopeptides from the NK09 donor showed a peptide lacking 
the L residue. N-glycan cartoons represent one possible configuration based on composition. 
See also Table 2 and Figure S4. 
  
  
 at K
arolinska Inst U
niv Lib on Septem
ber 8, 2019
http://w
w
w
.m
cponline.org/
D
ow
nloaded from
 
 37 
 
 
Figure 7. NK cells retain IgG1 lacking core fucose. A. Flow cytometry showing the 
collinearity of IgG and CD16a staining on primary human NK cells following cell isolation. B. 
Sources of IgG molecules (depicted as Y-shaped symbols). The top ten fucosylated and 
afucosylated IgG1 glycoforms isolated from primary NK cells (C.) and serum (D.). See also 
Tables S3 and S4. 
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